Presentaciones orales

Dongen, et al J. Van

doi:10.7705/biomedica.v30i0.825

Cited by 8 publications

(17 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, these markers were considered backbone markers from start onwards, based on our previous experience. 10,12,18,[28][29][30] Also, CD38 is present in all proposed panels and was proven to be relevant in our present study as well as in the studies of Karawajew et al 14 and Shaver et al 15 The remaining 2 positions were completed with different Using the bulk-lysis method, significantly less debris (P 5 .032 by paired Student t test) and significantly more leukocytes (P 5 .03 by paired Student t test) were measured. There were no significant differences between the 2 methods for the percentage of doublets.…”

Section: Discussionsupporting

confidence: 50%

“…Fluorochrome positions were primarily determined based on the position of the involved markers in the EuroFlow BCP-ALL panel. 18 The resulting 3 phase 1 MRD tubes (Table 2) were subsequently tested on 61 consecutive BCP-ALL patients at diagnosis, and the discriminatory power was evaluated by comparing the leukemic BCP with the nearest normal BCP subset in APS plots. Whereas both tube 1 and tube 3 gave good/fair separation in ;60% of cases, tube 2 was clearly less informative (fair/good separation in ,35% of cases) (Figure 2).…”

Section: Resultsmentioning

confidence: 99%

“…10,[28][29][30] To evaluate which other markers could contribute to optimal separation of BCP-ALL cells from normal/ reactive BCP cells, the EuroFlow BCP-ALL diagnosis panel 18 was applied to 69 BCP-ALL patients as well as to normal/reactive BM samples. Based on principal component analysis (visualized through APS plots) 16,17,19 of the BCP-ALL cells vs normal/reactive BCP cells (analyzed per tube), CD9, CD123, CD66c, CD81, CD24, and CD10 appeared to be markers that were most frequently differentially expressed (see supplemental Figure 5).…”

Section: Resultsmentioning

confidence: 99%

“…18 The subsequently designed and optimized MRD tubes were tested during phase 1 to 4 on diagnostic BM samples from BCP-ALL patients using the standardized EuroFlow sample preparation and instrument setup protocols. 18,19 Data were analyzed using Infinicyt software by comparing BCP-ALL cells with the nearest normal/reactive BCP subsets using automated population separator (APS) plots (see supplemental Methods, available on the Blood Web site) as illustrated in Figure 1 and supplemental Figures 1 and 2. Regenerating BCP cells from 6 T-ALL patients were used as an additional negative control (supplemental Figure 3).…”

Section: Immunophenotyping Mrd Panel Designmentioning

confidence: 99%

See 3 more Smart Citations

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

Theunissen

Mejstříková

Sędek

et al. 2017

Blood

335

296

View full text Add to dashboard Cite

Key Points• Standardized flow cytometry allows highly sensitive MRD measurements in virtually all BCP-ALL patients.• If sufficient cells are measured (.4 million), flow cytometric MRD analysis is at least as sensitive as current PCR-based MRD methods.A fully-standardized EuroFlow 8-color antibody panel and laboratory procedure was stepwise designed to measure minimal residual disease (MRD) in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) patients with a sensitivity of £10 25, comparable to real-time quantitative polymerase chain reaction (RQ-PCR)-based MRD detection via antigen-receptor rearrangements. Leukocyte markers and the corresponding antibodies and fluorochromes were selected based on their contribution in separating BCP-ALL cells from normal/regenerating BCP cells in multidimensional principal component analyses. After 5 multicenter design-test-evaluate-redesign phases with a total of 319 BCP-ALL patients at diagnosis, two 8-color antibody tubes were selected, which allowed separation between normal and malignant BCP cells in 99% of studied patients. These 2 tubes were tested with a new erythrocyte bulk-lysis protocol allowing acquisition of high cell numbers in 377 bone marrow follow-up samples of 178 BCP-ALL patients.Comparison with RQ-PCR-based MRD data showed a clear positive relation between the percentage concordant cases and the number of cells acquired. For those samples with >4 million cells acquired, concordant results were obtained in 93% of samples. Most discordances were clarified upon high-throughput sequencing of antigen-receptor rearrangements and blind multicenter reanalysis of flow cytometric data, resulting in an unprecedented concordance of 98% (97% for samples with MRD < 0.01%). In conclusion, the fully standardized EuroFlow BCP-ALL MRD strategy is applicable in >98% of patients with sensitivities at least similar to RQ-PCR (£10 25 ), if sufficient cells (>4 3 10 6 , preferably more) are evaluated. (Blood. 2017;129(3):347-357)

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Immunophenotyping Mrd Panel Designmentioning

confidence: 99%

See 2 more Smart Citations

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

Theunissen

Mejstříková

Sędek

et al. 2017

Blood

335

296

View full text Add to dashboard Cite

show abstract

“…This requires fully standardized approaches, including instrument setting, sample processing with bulk lysis procedure, immunostaining, data acquisition, and data analysis with standardized (even automated) gating strategies for definition of cell populations 102,103 ; see www. EuroFlow.org for standard operating procedures (Table 3).…”

mentioning

confidence: 99%

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

Dongen

Velden

Brüggemann

et al. 2015

Blood

415

384

View full text Add to dashboard Cite

Monitoring of minimal residual disease (MRD) has become routine clinical practice in frontline treatment of virtually all childhood acute lymphoblastic leukemia (ALL) and in many adult ALL patients. MRD diagnostics has proven to be the strongest prognostic factor, allowing for risk group assignment into different treatment arms, ranging from significant treatment reduction to mild or strong intensification. Also in relapsed ALL patients and patients undergoing stem cell transplantation, MRD diagnostics is guiding treatment decisions. This is also why the efficacy of innovative drugs, such as antibodies and small molecules, are currently being evaluated with MRD diagnostics within clinical trials. In fact, MRD measurements might well be used as a surrogate end point, thereby significantly shortening the follow-up. The MRD techniques need to be sensitive (≤10−4), broadly applicable, accurate, reliable, fast, and affordable. Thus far, flow cytometry and polymerase chain reaction (PCR) analysis of rearranged immunoglobulin and T-cell receptor genes (allele-specific oligonucleotide [ASO]-PCR) are claimed to meet these criteria, but classical flow cytometry does not reach a solid 10−4, whereas classical ASO-PCR is time-consuming and labor intensive. Therefore, 2 high-throughput technologies are being explored, ie, high-throughput sequencing and next-generation (multidimensional) flow cytometry, both evaluating millions of sequences or cells, respectively. Each of them has specific advantages and disadvantages.

show abstract

Productive explanation: A framework for evaluating explanations in psychological science.

van Dongen,

van Bork,

Finnemann

et al. 2024

Psychological Review

View full text Add to dashboard Cite

Presentaciones orales

Cited by 8 publications

References 6 publications

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

Productive explanation: A framework for evaluating explanations in psychological science.

Contact Info

Product

Resources

About